We are live on ! Find out more
ORTX

Orchard Therapeutics plc American Depositary Shares

Delisted

ORTX was delisted on the 23rd of January, 2024.

43 hedge funds and large institutions have $875M invested in Orchard Therapeutics plc American Depositary Shares in 2019 Q1 according to their latest regulatory filings, with 11 funds opening new positions, 9 increasing their positions, 12 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

120% more first-time investments, than exits

New positions opened: 11 | Existing positions closed: 5

16% more funds holding

Funds holding: 3743 (+6)

14% more capital invested

Capital invested by funds: $765M → $875M (+$110M)

0% more funds holding in top 10

Funds holding in top 10: 55 (0)

25% less repeat investments, than reductions

Existing positions increased: 9 | Existing positions reduced: 12

Holders
43
Holders Change
+6
Holders Change %
+16.22%
% of All Funds
0.93%
Holding in Top 10
5
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.11%
New
11
Increased
9
Reduced
12
Closed
5
Calls
Puts
Net Calls
Net Calls Change
Name Holding Trade Value Shares
Change
Change in
Stake
Fidelity Investments
1
Fidelity Investments
Massachusetts
$365M
DM
2
Deerfield Management
New York
$143M
RCM
3
RA Capital Management
Massachusetts
$91.3M +$3.94M +26,240 +5%
CI
4
Cowen Inc
New York
$52M -$303K -2,015 -0.7%
T. Rowe Price Associates
5
T. Rowe Price Associates
Maryland
$36.3M +$1.79M +11,916 +6%
Adage Capital Partners
6
Adage Capital Partners
Massachusetts
$19.2M
Temasek Holdings
7
Temasek Holdings
Singapore
$17.9M
Baillie Gifford & Co
8
Baillie Gifford & Co
United Kingdom
$16.5M
DCM
9
Driehaus Capital Management
Illinois
$15.5M +$138K +916 +1%
VMI
10
VHCP Management III
New York
$14.5M -$3.46M -23,049 -22%
ACH
11
ArrowMark Colorado Holdings
Colorado
$12.7M +$1.05M +6,985 +11%
CAM
12
Cormorant Asset Management
Massachusetts
$11.6M +$4.14M +27,514 +73%
Westfield Capital Management
13
Westfield Capital Management
Massachusetts
$9.35M +$7.86M +52,269 New
PA
14
Perceptive Advisors
New York
$9.33M
VC
15
Vivo Capital
California
$8.61M -$4.96M -33,028 -41%
Massachusetts Financial Services
16
Massachusetts Financial Services
Massachusetts
$7.89M -$4.51K -30 -0.1%
PI
17
Putnam Investments
Massachusetts
$6.82M +$5.73M +38,130 New
GTC
18
Ghost Tree Capital
New York
$5.36M
SI
19
Sofinnova Investments
California
$4.94M +$804K +5,346 +24%
Millennium Management
20
Millennium Management
New York
$4.9M -$230K -1,532 -5%
EAM
21
Eventide Asset Management
Massachusetts
$4.83M
SFM
22
Sphera Funds Management
Israel
$3.54M -$2.59M -17,221 -47%
EU
23
Emory University
Georgia
$2.8M +$2.35M +15,640 New
BBA
24
Baker Bros. Advisors
New York
$2.23M
BCP
25
Berylson Capital Partners
Massachusetts
$2.17M +$1.82M +12,135 New

ORTX Hedge Fund Activity: Q1 2019 in Review

43 of the 4,621 institutional investors tracked by Wall St. Rank reported a position in Orchard Therapeutics plc American Depositary Shares (ORTX) for Q1 2019, worth a combined $875M — up 14% from $765M a quarter earlier.

Buyers outnumbered sellers: 11 funds opened new ORTX positions and 5 closed out — a net gain of 6 holders — while 9 added to existing stakes and 12 trimmed.

The largest buyer was Westfield Capital Management, opening a new position worth an estimated $7.86M. The largest seller was Foresite Capital Management IV, exiting entirely with an estimated $10.5M sold.

  • 43 institutional investors held Orchard Therapeutics plc American Depositary Shares (ORTX) as of Q1 2019, up from 37 in Q4 2018.
  • Funds reported $875M of Orchard Therapeutics plc American Depositary Shares stock for Q1 2019, up 14% quarter-over-quarter.
  • 11 funds opened new Orchard Therapeutics plc American Depositary Shares positions in Q1 2019 and 5 closed out, a net change of +6 holders.
  • The largest Orchard Therapeutics plc American Depositary Shares buyer in Q1 2019 was Westfield Capital Management, an estimated $7.86M added.
  • The largest Orchard Therapeutics plc American Depositary Shares seller in Q1 2019 was Foresite Capital Management IV, an estimated $10.5M sold.

Based on aggregated 13F filings for Q1 2019.